Leveraging Finch’s machine learning expertise in C. diff. and beyond

CEO Mark Smith describes the vast potential of the microbiome and Finch’s therapeutic platforms:

“We think the microbiome is really fundamental to many aspects of who we are, how our immune systems function, how we regulate our metabolism and how we think and feel,’ says Smith, who predicts ‘broad potential across a number of therapeutic areas.”